register

News & Trends - Pharmaceuticals

GSK welcomes government commitment to purchase the first treatment for mild-moderate COVID-19

Health Industry Hub | August 9, 2021 |
[Total: 2    Average: 4.5/5]

Pharma News: Australians are set to have access to a new treatment for COVID-19, in addition to the continuously expanding the existing vaccine rollout.

GSK Australia has signed an agreement with the Australian Government to purchase its new COVID-19 treatment, once approved by the Therapeutic Goods Administration’s (TGA).

The TGA previously granted GSK’s sotrovimab a provisional determination in April 2021, which provides a mechanism for accelerating the provisional registration of promising new medicines. If it receives provisional approval from the TGA, it will be the first treatment to receive regulatory approval to treat early stage COVID-19 in Australia.

The Australian Government’s agreement with GSK includes delivery of more than 7,700 doses for the National Medical Stockpile, with an initial delivery this year upon TGA approval.

The advanced purchase of sotrovimab has been supported by the Science and Industry Technical Advisory Group (SITAG), which is the Australian Government’s expert group advising on COVID-19 vaccine and treatment purchases.

Dr Krystal Evans, Medical Lead for COVID Therapeutics at GSK Australia, said that the company is pleased to be part of ensuring the Australian community are able to have an early treatment option against COVID-19.

“GSK is committed to partnering with the Australian Government to ensure Australians get prompt access to emerging treatments once they have been approved by the appropriate regulators,” Dr Evans commented.

Treatment with sotrovimab resulted in an 85% reduction in the risk of hospitalisation or death in high-risk adult outpatients compared to placebo, based on interim results from Phase 3 COMET-ICE trial. In vitro data indicates sotrovimab maintains activity against all known variants of concern.

Sotrovimab will be the first COVID-19 monoclonal antibody treatment available for use in this country, with the complete treatment requiring just one dose administered via IV infusion in a healthcare facility.

Where a doctor prescribes this treatment for their patients with mild to moderate COVID-19, who are at risk of developing severe COVID-19, it will be made available free of charge through the public health system.

Clinician estimates of the Australian patient treatment population range from 8-15% of patients who are SARS-CoV2 positive that would be considered at high risk of disease progression and would be recommended for treatment with sotrovimab, based on past and current experience of managing COVID-19 patients.


News & Trends - Medical Technology

Calls for independent review of private health insurance as profits sky rocket and consumers lose out

Health Industry Hub | May 27, 2022 |

MedTech News: The Consumers Health Forum is again calling for an independent review of private health insurance as the Australian […]

More


Social Responsibility

J&J Medtech, Pfizer and Baxter Healthcare take action to ‘make change’ this National Reconciliation Week

Health Industry Hub | May 27, 2022 |

On election night, Anthony Albanese opened his acceptance speech with a full commitment to the Uluru Statement From the Heart. […]

More


News & Trends - Medical Technology

Surgical procedures postponed amid shortage of medical imaging

Health Industry Hub | May 27, 2022 |

MedTech News: Queensland Health will reschedule some non-urgent elective procedures due to a critical world-wide shortage of contrast solutions required […]

More


News & Trends - Medical Technology

Elective surgery wait times ‘longer than they have ever been’ in private hospitals

Health Industry Hub | May 27, 2022 |

MedTech News: A sharp increase in ‘missing’ episodes of care in Australia’s private hospitals in the first quarter of 2022 […]

More


This content is copyright protected